Exsilio Therapeutics, a biotechnology company developing genomic medicines, emerged from stealth raising USD 82 million in a Series A funding round co-led by Novartis Venture Fund and Delos Capital, with participation from OrbiMed, Insight Partners, CRISPR Therapeutics, and others.
The funding will advance Exsilio's platform for developing genomic medicines based on naturally occurring genetic elements that can be delivered via mRNA and lipid nanoparticles to insert therapeutic genes into the human genome.
Exsilio is developing a new class of genomic medicines that leverages mRNA technology to deliver genes that can permanently integrate into cells, offering the possibility of curative effects. The company's platform combines predictive modeling and experimentation to engineer genetic elements for precise gene insertion into safe harbor sites in the genome. The approach aims to enable redosable and titratable genomic medicines for genetic diseases, cancer, and autoimmune conditions.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.